Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1998 2
1999 5
2000 7
2002 3
2003 3
2004 5
2005 3
2006 4
2007 1
2008 1
2009 1
2011 2
2013 2
2014 3
2019 3
2021 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Effects of zolpidem and zaleplon on cognitive performance after emergent morning awakenings at Tmax: a randomized placebo-controlled trial.
Dinges DF, Basner M, Ecker AJ, Baskin P, Johnston SL. Dinges DF, et al. Sleep. 2019 Mar 1;42(3):zsy258. doi: 10.1093/sleep/zsy258. Sleep. 2019. PMID: 30576525 Clinical Trial.
To evaluate the risk to operational safety, a ground-based, double-blind, placebo-controlled study on the emergent awakening effects of zolpidem and zaleplon was conducted. METHODS: N = 34 participants (age M = 42.1 9.7; 25 males; 9 Astronauts, 7 Astronaut candidates, and …
To evaluate the risk to operational safety, a ground-based, double-blind, placebo-controlled study on the emergent awakening effects of zolp …
Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
Citrome L, Juday T, Frech F, Atkins N Jr. Citrome L, et al. J Clin Psychiatry. 2021 Jun 1;82:20m13795. doi: 10.4088/JCP.20m13795. J Clin Psychiatry. 2021. PMID: 34077032 Free article. Clinical Trial.
Direct comparisons were made with zolpidem extended release (ER), and indirect comparisons were made with other hypnotic agents, including suvorexant, doxepin, ramelteon, zolpidem immediate release, eszopiclone, zaleplon, and selected benzodiazepines, using data from publi …
Direct comparisons were made with zolpidem extended release (ER), and indirect comparisons were made with other hypnotic agents, including s …
Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group.
Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Hedner J, et al. Int J Geriatr Psychiatry. 2000 Aug;15(8):704-12. doi: 10.1002/1099-1166(200008)15:8<704::aid-gps183>3.0.co;2-s. Int J Geriatr Psychiatry. 2000. PMID: 10960882 Clinical Trial.
The pharmacology and pharmacokinetics of Zaleplon suggest a safety profile that is improved over other hypnotics. The objective of this placebo-controlled study was to evaluate the efficacy and safety of Zaleplon (5 and 10 mg) in elderly (> or =65 years) outpatie …
The pharmacology and pharmacokinetics of Zaleplon suggest a safety profile that is improved over other hypnotics. The objective of th …
Impact of zaleplon on continuous positive airway pressure therapy compliance.
Park JG, Olson EJ, Morgenthaler TI. Park JG, et al. J Clin Sleep Med. 2013 May 15;9(5):439-44. doi: 10.5664/jcsm.2660. J Clin Sleep Med. 2013. PMID: 23674934 Free PMC article. Clinical Trial.
STUDY OBJECTIVE: To determine whether pretreatment with zaleplon immediately before CPAP titration improves 1-month CPAP adherence in subjects newly diagnosed with OSA. ...RESULTS: One hundred thirty-four newly diagnosed OSA patients undergoing their initial split-night PS …
STUDY OBJECTIVE: To determine whether pretreatment with zaleplon immediately before CPAP titration improves 1-month CPAP adherence in …
Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.
Zammit GK, Corser B, Doghramji K, Fry JM, James S, Krystal A, Mangano RM. Zammit GK, et al. J Clin Sleep Med. 2006 Oct 15;2(4):417-23. J Clin Sleep Med. 2006. PMID: 17557470 Clinical Trial.
Residual sedation was not detected as little as 4 hours after zaleplon 10 mg, whereas residual sedation was detected with zolpidem 10 mg up to 7 hours after treatment. These findings suggest that zaleplon may be an appropriate treatment for use when patients awaken …
Residual sedation was not detected as little as 4 hours after zaleplon 10 mg, whereas residual sedation was detected with zolpidem 10 …
The pharmacokinetics and pharmacodynamics of zaleplon delivered as a thermally generated aerosol in a single breath to volunteers.
Avram MJ, Spyker DA, Kehne JH, Cassella JV. Avram MJ, et al. J Clin Pharmacol. 2013 Feb;53(2):140-50. doi: 10.1177/0091270012436886. J Clin Pharmacol. 2013. PMID: 23436259 Clinical Trial.
Pharmacokinetics, pharmacodynamics, safety, and tolerability of inhaled zaleplon were assessed in healthy volunteers. Forty participants received 0.5, 1, 2, or 4 mg zaleplon or placebo as a thermally generated aerosol in a randomized, double-blind, parallel-group, d …
Pharmacokinetics, pharmacodynamics, safety, and tolerability of inhaled zaleplon were assessed in healthy volunteers. Forty participa …
Zaleplon and triazolam in humans: acute behavioral effects and abuse potential.
Rush CR, Frey JM, Griffiths RR. Rush CR, et al. Psychopharmacology (Berl). 1999 Jul;145(1):39-51. doi: 10.1007/s002130051030. Psychopharmacology (Berl). 1999. PMID: 10445371 Clinical Trial.
Zaleplon and triazolam produced comparable dose-related effects on several subject-rated drug-effect questionnaires. ...The onset time, time to maximum drug effect, and duration of action were shorter with zaleplon than triazolam. Thus, despite its non-benzodiazepin …
Zaleplon and triazolam produced comparable dose-related effects on several subject-rated drug-effect questionnaires. ...The onset tim …
Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.
Greenblatt DJ, Harmatz JS, von Moltke LL, Ehrenberg BL, Harrel L, Corbett K, Counihan M, Graf JA, Darwish M, Mertzanis P, Martin PT, Cevallos WH, Shader RI. Greenblatt DJ, et al. Clin Pharmacol Ther. 1998 Nov;64(5):553-61. doi: 10.1016/S0009-9236(98)90139-4. Clin Pharmacol Ther. 1998. PMID: 9834048 Clinical Trial.

The overall order of agonist potency was as follows: placebo < 10 mg zaleplon < 20 mg zaleplon < 10 mg zolpidem < 20 mg zolpidem; on a number of measures, 20 mg zaleplon was comparable to 10 mg zolpidem. ...CONCLUSIONS: Benzodiazepine agonist effe

…

The overall order of agonist potency was as follows: placebo < 10 mg zaleplon < 20 mg zaleplon < 10 mg zolpidem <

…
Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group.
Fry J, Scharf M, Mangano R, Fujimori M. Fry J, et al. Int Clin Psychopharmacol. 2000 May;15(3):141-52. doi: 10.1097/00004850-200015030-00003. Int Clin Psychopharmacol. 2000. PMID: 10870872 Clinical Trial.
During week 1, sleep latency was significantly shorter with zaleplon 5, 10, and 20 mg compared to placebo. The significant decrease in sleep latency persisted through week 4 with zaleplon 20 mg, and was again evident with zaleplon 10 mg at week 3. Zaleplon …
During week 1, sleep latency was significantly shorter with zaleplon 5, 10, and 20 mg compared to placebo. The significant decrease i …
Zaleplon pharmacokinetics and absolute bioavailability.
Rosen AS, Fournié P, Darwish M, Danjou P, Troy SM. Rosen AS, et al. Biopharm Drug Dispos. 1999 Apr;20(3):171-5. doi: 10.1002/(sici)1099-081x(199904)20:3<171::aid-bdd169>3.0.co;2-k. Biopharm Drug Dispos. 1999. PMID: 10211871 Clinical Trial.
Subjects received 1 and 2.5 mg intravenous (i.v.) infusions of zaleplon during the first and second periods, respectively, and then were randomly assigned to receive a 5 mg oral dose or 5 mg i.v. infusion of zaleplon in a crossover design during the final two period …
Subjects received 1 and 2.5 mg intravenous (i.v.) infusions of zaleplon during the first and second periods, respectively, and then w …
47 results